Sustained anti-TNFα therapy has been shown to heighten the risk of infections [5], [6], which can be considered a reflection of the delicate balance of innate immunity, where abundant activation may cause collateral damage (such as in sepsis and endotoxemia) while modest activation serves to protect the host against invading pathogens [7], [8]. This evidence concerns the gene TNF and serum lipopolysaccharide activity.